News from CSL Behring Canada A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 25, 2017, 08:00 ET HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema

Global biotherapeutics leader CSL Behring announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...


Jul 21, 2017, 09:54 ET CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of...


Jul 19, 2017, 09:30 ET FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's...


Jul 12, 2017, 09:00 ET New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B

CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low...


Jul 11, 2017, 06:30 ET CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society's annual meeting the winners of its annual Interlaken...


Jul 10, 2017, 09:00 ET New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A

CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in...


Jul 06, 2017, 09:00 ET New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017

CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...


Jun 23, 2017, 14:16 ET FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved...


May 19, 2017, 08:00 ET New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award

CSL Behring received the National Organization for Rare Disorders' (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...


Apr 19, 2017, 14:00 ET Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA®...


Apr 10, 2017, 11:00 ET Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 4...


Mar 31, 2017, 10:00 ET La Fondation Jeffrey Modell va déployer le premier réseau nord-africain pour le traitement de l'immunodéficience primaire

CSL Behring sponsorise le premier réseau de ce genre sur le continent africain Le leader mondial des produits biothérapeutiques CSL Behring...


Mar 31, 2017, 10:00 ET Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...


Mar 29, 2017, 15:30 ET CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...


Mar 22, 2017, 17:16 ET New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the...


Mar 01, 2017, 09:25 ET Largest Ever CIDP Clinical Study Completed

Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...


Feb 14, 2017, 09:30 ET FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's...


Jan 09, 2017, 09:55 ET AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA®...


Dec 22, 2016, 10:00 ET CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

CSL Limited (ASX: CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its...


Dec 14, 2016, 13:58 ET Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A

-AFSTYLA is the first and only single-chain recombinant factor VIII for hemophilia A, specifically designed for long-lasting protection from bleeds...


Dec 03, 2016, 20:30 ET CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION®...


Dec 02, 2016, 09:51 ET The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

Global biotherapeutics leader CSL Behring announced today that The Lancet Respiratory Medicine, a specialty journal, published findings of the...


Nov 15, 2016, 13:25 ET CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial

CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel...


Nov 14, 2016, 10:00 ET AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use...


Oct 27, 2016, 14:30 ET CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products...